What is Nalidixic Acid used for?

Nalidixic acid, a pioneering antibacterial agent, has had a significant place in the treatment of bacterial infections since its discovery in the early 1960s. Known under various trade names such as NegGram, Wintomylon, and Uriben, this synthetic antibiotic belongs to the quinolone class of drugs. It was developed by George Y. Lesher and colleagues at the Sterling-Winthrop Research Institute. Nalidixic acid primarily targets gram-negative bacteria and is particularly effective against pathogens causing urinary tract infections (UTIs). Its role extends to combating infections caused by species such as Escherichia coli, Shigella, and Proteus. Although newer generations of quinolones have emerged, leading to more advanced treatments, nalidixic acid remains pertinent in certain clinical settings, largely owing to its cost-effectiveness and efficacy in specific bacterial infections.

Nalidixic acid operates through a well-defined mechanism of action that primarily involves the inhibition of bacterial DNA synthesis. The drug targets bacterial DNA gyrase, an enzyme critical for DNA replication. By binding to the A-subunit of DNA gyrase, nalidixic acid interrupts the supercoiling process of bacterial DNA, thereby halting replication and transcription. This inhibition ultimately leads to bacterial cell death. It is this bactericidal property that underpins its clinical utility. Unlike broad-spectrum antibiotics that may target a wide range of bacteria, nalidixic acid is more selective, focusing on gram-negative organisms. This selectivity is advantageous in reducing the risk of disrupting the body's normal microbiota while effectively dealing with pathogenic bacteria.

 

Researching Nalidixic Acid beyond the basics?

Synapse Hiro LS Researcher, the Synapse AI Insight Engine, is built to accelerate biopharma decisions. Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence. Explore Nalidixic Acid with Hiro LS Researcher →

When it comes to administration, nalidixic acid is typically prescribed in oral form, available as tablets or liquid suspensions. The usual adult dosage is 1 gram every six hours, although this may be adjusted based on the severity of the infection and the patient's renal function. For pediatric use, the dosage is generally calculated based on body weight. It is crucial to complete the entire prescribed course of nalidixic acid to ensure the eradication of the infection and to mitigate the risk of resistance development. The onset of action for nalidixic acid is relatively rapid, with therapeutic levels achieved in the bloodstream within one to two hours of ingestion. Patients can expect to notice symptom relief within a few days, although the exact timeline may vary depending on the nature and severity of the infection.

Despite its efficacy, nalidixic acid is not without side effects. Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Some patients may also experience headache, dizziness, or visual disturbances. More severe side effects, although less common, can include hypersensitivity reactions, blood dyscrasias, or signs of central nervous system toxicity such as seizures. Given the potential for serious adverse effects, nalidixic acid is contraindicated in individuals with a history of hypersensitivity to quinolones. It should also be used with caution in patients with renal impairment or those with a history of seizures. Pregnant women and children under the age of three months are generally advised against using nalidixic acid due to potential risks to fetal and infant development.

Interactions with other drugs can influence the efficacy and safety profile of nalidixic acid. For instance, concurrent use of antacids containing magnesium or aluminum can reduce the absorption of nalidixic acid, leading to subtherapeutic levels. Similarly, co-administration with anticoagulants such as warfarin can potentiate the anticoagulant effect, thereby increasing the risk of bleeding. Other drugs that may interact with nalidixic acid include non-steroidal anti-inflammatory drugs (NSAIDs), which can exacerbate the risk of central nervous system side effects, and probenecid, which can inhibit renal excretion of the acid, leading to elevated serum levels. It is imperative for healthcare providers to thoroughly review a patient's medication history before initiating nalidixic acid therapy to avoid potential drug interactions.

In summary, nalidixic acid holds a distinctive place in the antibiotic arsenal, particularly for the treatment of urinary tract infections caused by gram-negative bacteria. Its mechanism of action, involving the inhibition of bacterial DNA gyrase, underscores its effectiveness. However, careful consideration of potential side effects, contraindications, and drug interactions is essential to ensure safe and effective use. Despite the advent of newer antibiotics, nalidixic acid remains a valuable option in specific clinical scenarios, underscoring the enduring relevance of this early quinolone antibiotic.

Continue your Nalidixic Acid research with Synapse Hiro LS Researcher

This article provides an overview. For a broader research view, use Synapse Hiro LS Researcher—the Synapse AI Insight Engine—to search across drugs, targets, indications, clinical trials, literature, organizations, news, deals, and competitor signals. Ask any biopharma research question in natural language.

Questions to explore:

• What approved and investigational uses have been reported for Nalidixic Acid?
• What is the mechanism of action of Nalidixic Acid, and which targets or pathways are involved?
• Which clinical trials are evaluating Nalidixic Acid, and what outcomes have been reported?
• What patents, publications, and regulatory sources provide the latest evidence on Nalidixic Acid?

Ask Synapse Hiro LS Researcher →

AI may make mistakes. Check important info.